Faeth Therapeutics, Inc. (FTH) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$18.36M*; Operating income -$18.39M; Depreciation and amortization $25.00K*.
- 2026-03-31: Basis Reported; EBITDA -$170.6M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$4.93M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$4.82M*; Operating income -$4.85M; Depreciation and amortization $30.00K*.
Complete source-backed ebitda history.
- Available history
- 2020-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$18.36M* | -$18.39M | $25.00K* | (m) | (m) | $0.00* | -$15.67M* | (m) | (m) | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$170.6M | (m) | (m) | (m) | (m) | $6.00K | -$10.73M | (m) | (m) | (m) | $0.00 |
|---|
| 2025-12-31 | Reported | -$4.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$4.82M* | -$4.85M | $30.00K* | (m) | (m) | $0.00* | -$3.59M* | (m) | (m) | (m) | $0.00* |
|---|
| 2025-06-30 | Reported | -$5.17M* | -$5.21M | $32.00K* | (m) | (m) | $16.00K* | -$5.91M* | (m) | (m) | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$7.24M | (m) | (m) | (m) | (m) | $0.00 | -$7.09M | (m) | (m) | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$8.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$7.68M | (m) | (m) | (m) | (m) | $0.00* | -$5.47M* | (m) | (m) | (m) | $0.00* |
|---|
| 2024-06-30 | Reported | -$7.65M | (m) | (m) | (m) | (m) | $109.00K* | -$5.79M* | (m) | (m) | (m) | $0.00* |
|---|
| 2024-03-31 | Reported | -$8.59M | (m) | (m) | (m) | (m) | $37.00K | -$7.62M | (m) | (m) | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$8.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$7.6M | (m) | (m) | (m) | (m) | $0.00* | -$4.66M* | (m) | (m) | (m) | $0.00* |
|---|
| 2023-06-30 | Reported | -$10.04M | (m) | (m) | (m) | (m) | $29.00K* | -$9.46M* | (m) | (m) | (m) | $0.00* |
|---|
| 2023-03-31 | Reported | -$10.85M | (m) | (m) | (m) | (m) | $151.00K | -$11.74M | (m) | (m) | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | -$12.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$13.79M | (m) | (m) | (m) | (m) | $250.00K* | -$6.80M* | (m) | (m) | (m) | $0.00* |
|---|
| 2022-06-30 | Reported | -$10.57M | (m) | (m) | (m) | (m) | $52.00K* | -$11.90M* | (m) | (m) | (m) | $0.00* |
|---|
| 2022-03-31 | Reported | -$12.33M | (m) | (m) | (m) | (m) | $19.00K | -$10.75M | (m) | (m) | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | -$9.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$10.18M | (m) | (m) | (m) | (m) | $388.00K* | -$5.58M* | (m) | (m) | (m) | $0.00 |
|---|
| 2021-06-30 | Reported | -$9.66M | (m) | (m) | (m) | (m) | $616.00K* | -$6.05M* | (m) | (m) | (m) | $0.00 |
|---|
| 2021-03-31 | Reported | -$7.87M | (m) | (m) | (m) | (m) | $487.00K | -$10.77M | (m) | $3.37M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$5.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$5.3M | (m) | (m) | (m) | (m) | $836.00K* | -$5.80M* | (m) | (m) | (m) | $0.00 |
|---|
| 2020-06-30 | Reported | -$4.86M | (m) | (m) | (m) | (m) | $2.00K* | -$2.77M* | (m) | (m) | (m) | $0.00 |
|---|
| 2020-03-31 | Reported | -$4.08M | (m) | (m) | (m) | (m) | $52.00K | -$6.46M | (m) | $2.19M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$22.17M | (m) | (m) | (m) | (m) | $16.00K | -$20.45M | (m) | (m) | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$32.06M | (m) | (m) | (m) | (m) | $146.00K | -$24.67M | (m) | (m) | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$36.49M | (m) | (m) | (m) | (m) | $180.00K | -$32.02M | (m) | (m) | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$49.57M | (m) | (m) | (m) | (m) | $321.00K | -$39.03M | (m) | (m) | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$36.8M | (m) | (m) | (m) | (m) | $2.03M | -$30.26M | (m) | (m) | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$19.24M | (m) | (m) | (m) | (m) | $1.21M | -$17.70M | (m) | (m) | (m) | (m) |
|---|